Greg van Wyk, MD is Chief Executive Officer & Chief Medical Officer of Noxopharm.
He graduated as a medical doctor, from the University of the Witwatersrand (Johannesburg, South Africa), in 2001 and worked clinically for 5 years prior to moving into pharmaceutical medicine. Prior to joining Noxopharm, he enjoyed an 11-year career with Eli Lilly during which he led large, diverse medical teams and worked across a range of therapeutic areas on medicines in all stages.
In both clinical and commercial contexts, Greg is a strategic thinker who is focused on achieving valued outcomes for the multitude of stakeholders engaged with the pharmaceutical industry. He enjoys research design and analysis and he enjoys continuous learning. Greg has postgraduate degrees in management and economics and is passionate about the healthcare economy and the role of technology in extending and enhancing people's lives. He is also a non-executive director of ADHD Australia, a not for profit organization aiming to make Australia a better place for people affected by ADHD.
Onco’Zine, The International Oncology Network (ISSN 2168-5339) is published by Sunvalley Communication, LLC. The journal publishes a broad range of topics and timely news updates with information from all oncology disciplines and sub-specialties from around the world. Onco’Zine is a sponsor-supported, interactive online community for healthcare professionals and other medical specialists involved in the management and care of cancer patients.